Crinetics will hold a live webcast on Tuesday, March 19 at 8:30 a.m. ET to discuss topline results from PATHFNDR-2, the second of two Phase 3 studies evaluating the efficacy and safety of oral, once-daily investigational paltusotine for the treatment of acromegaly.
News & Events
Topline Results from Paltusotine Phase 3 PATHFNDR-2 Study
Transforming Endocrine Disease Treatment
Be the first to know about the advances we're making in endocrine care.